PROGNOSTIC HETEROGENEITY AMONG HIGH RISK MULTIPLE MYELOMA PATIENTS (T(4-14) AND DEL17P) ACCORDING TO ADDITIONAL CYTOGENETIC ABNORMALITIES, THE IFM EXPERIENCE

被引：0

作者：

Benjamin, H. ^{[1
]}

Florence, M. ^{[2
]}

Alice, C. ^{[3
,4
]}

Valerie, L. C. ^{[1
]}

Marie-Lorraine, C. ^{[5
]}

Cyrille, H. ^{[6
]}

Xavier, L. ^{[7
]}

Gerald, M. ^{[8
]}

Lionel, K. ^{[9
]}

Murielle, R. ^{[1
]}

Philippe, R. ^{[10
]}

Catherine, S. ^{[9
]}

Francois, L. ^{[11
]}

Sabine, B. ^{[12
]}

Marie, S. Anne ^{[13
]}

Marc, W. ^{[14
]}

Frederique, O. P. ^{[15
]}

Sylvie, C. ^{[16
]}

Gerard, L. ^{[17
]}

Brrigitte, P. ^{[18
]}

Karim, B. ^{[19
]}

Jean, F. ^{[20
]}

Laurent, V. ^{[21
]}

Laurent, G. ^{[22
]}

Bruno, R. ^{[23
]}

Mamoun, D. ^{[24
]}

Margaret, M. ^{[25
]}

Denis, C. ^{[26
]}

Mohamad, M. ^{[22
]}

Thierry, F. ^{[7
]}

Philippe, M. ^{[27
]}

Michel, A. ^{[28
]}

Jill, C. ^{[29
,30
]}

Stephane, M. ^{[27
]}

Herve, A. L. ^{[31
,32
]}

机构：

[1] Hop Purpan, Toulouse, France

[2] UMR S 892, Nantes, France

[3] Hop Rangueil, Unite Genom Myelome, Toulouse, France

[4] Hop Rangueil, INSERM, U1037, CRCT, Toulouse, France

[5] Hop Dijon, Dijon, France

[6] Ctr Univ Nancy Brabois, Nancy, France

[7] CHRU Lille, F-59037 Lille, France

[8] Grp Hosp Haut Leveque, Bordeaux, France

[9] CHU Lyon, Lyon, France

[10] CH Perigueux, Perigueux, France

[11] CH DAX, Dax, France

[12] Hop Avicenne, Paris, France

[13] Inst J Paoli I Calmettes, F-13009 Marseille, France

[14] CH DUNKERQUE, Dunkerque, France

[15] CH Annecy, Annecy, France

[16] CH AIX, Aix En Provence, France

[17] CH AVIGNON, Avignon, France

[18] CH Grenoble, Grenoble, France

[19] AP HP, Paris, France

[20] CH Besancon, Besancon, France

[21] CH Chalon, Chalon Sur Saone, France

[22] CH St Antoine, Paris, France

[23] CH Amiens, Amiens, France

[24] CH Angers, Angers, France

[25] CH Caen, Caen, France

[26] CH DIJON, Dijon, France

[27] CHU Nantes, F-44035 Nantes 01, France

[28] Inst Claudius Regaud, Toulouse, France

[29] CHU Purpan, Unite Genom Myelome, Toulouse, France

[30] CHU Purpan, INSERM, U1037, CRCT, Toulouse, France

[31] CHU Toulouse, Unite Genom Myelome, Toulouse, France

[32] CHU Toulouse, INSERM, U1037, CRCT, Toulouse, France

来源：

HAEMATOLOGICA | 2014年 / 99卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

S1287

引用

页码：495 / 495

页数：1

共 47 条

[31] Upfront stem cell transplantation for newly diagnosed multiple myeloma with del(17p) and t(4;14): a study from the CMWP-EBMT
Nico Gagelmann
Diderik-Jan Eikema
Liesbeth C. de Wreede
Alessandro Rambaldi
Simona Iacobelli
Linda Koster
Denis Caillot
Didier Blaise
Péter Remémyi
Claude-Eric Bulabois
Jakob Passweg
Xavier Leleu
Samo Zver
Guido Kobbe
Per Ljungman
Patrice Chevallier
Mark Ringhoffer
Murray Martin
Urpu Salmenniemi
Xavier Poiré
Stig Lenhoff
Pietro Pioltelli
Nicola Mordini
Michel Delforge
Laurent Garderet
Stefan Schönland
Ibrahim Yakoub-Agha
Nicolaus Kröger
Bone Marrow Transplantation, 2021, 56 : 210 - 217
[32] Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group
Grzasko, Norbert
Hajek, Roman
Hus, Marek
Chocholska, Sylwia
Morawska, Marta
Giannopoulos, Krzysztof
Czarnocki, Krzysztof
Druzd-Sitek, Agnieszka
Pienkowska-Grela, Barbara
Rygier, Jolanta
Usnarska-Zubkiewicz, Lidia
Dytfeld, Dominik
Kubicki, Tadeusz
Jurczyszyn, Artur
Korpysz, Maciej
Dmoszynska, Anna
LEUKEMIA & LYMPHOMA, 2017, 58 (09) : 2089 - 2100
[33] Lenalidomide overcomes poor prognosis conferred by del13q and t(4;14) but not del17p13 in multiple myeloma: Results of the Canadian MM016 trial
Bahlis, Nizar J.
Song, Kevin
Trieu, Young
Roland, Birgitte
Masih-Khan, Esther
Chang, Hong
Bruyere, Helene
Mansoor, Adnan
Horsman, Douglas
Eliasziw, Michael
Stewart, Douglas
Reece, Donna
BLOOD, 2007, 110 (11) : 1052A - 1052A
[34] Treatment Outcomes with Pomalidomide (POM) in Combination with Low-Dose Dexamethasone (LoDex) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM) and Del(17p13) and/or t(4;14)(p16;q32) Cytogenetic Abnormalities Who Have Received Prior Therapy with Lenalidomide (LEN) and Bortezomib (BORT)
Richardson, Paul G.
Jakubowiak, Andrzej
Bahlis, Nizar J.
Siegel, David S.
Chen, Christine I.
Chen, Min
Zaki, Mohamed
Larkins, Gail
Anderson, Kenneth C.
BLOOD, 2012, 120 (21)
[35] Total therapies (TT) for newly diagnosed patients with multiple myeloma (MM): Significant benefit in high-risk disease with cytogenetic abnormalities (CA) over the course of 17 years.
van Rhee, Frits
Bolejack, Vanessa
Anaissie, Elias
Tricot, Guido
Hollmig, Klaus
Zangari, Maurizio
Pineda-Roman, Mauricio
Mohiuddin, Abid
Hoering, Antje
Crowley, John
Barlogie, Bart
BLOOD, 2006, 108 (11) : 995A - 995A
[36] Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group (vol 58, pg 1, 2017)
Grzasko, R.
Hajek, R.
Hus, M.
LEUKEMIA & LYMPHOMA, 2017, 58 (10) : 2518 - 2518
[37] Combination of International Scoring System 3, High Lactate Dehydrogenase, and t(4;14) and/or del(17p) Identifies Patients With Multiple Myeloma (MM) Treated With Front-Line Autologous Stem-Cell Transplantation at High Risk of Early MM Progression-Related Death
Moreau, Philippe
Cavo, Michele
Sonneveld, Pieter
Rosinol, Laura
Attal, Michel
Pezzi, Annalisa
Goldschmidt, Hartmut
Lahuerta, Juan Jose
Marit, Gerald
Palumbo, Antonio
van der Holt, Bronno
Blade, Joan
Petrucci, Maria Teresa
Neben, Kai
san Miguel, Jesus
Patriarca, Francesca
Lokhorst, Henk
Zamagni, Elena
Hulin, Cyrille
Gutierrez, Norma
Facon, Thierry
Caillot, Denis
Benboubker, Lotfi
Harousseau, Jean-Luc
Leleu, Xavier
Avet-Loiseau, Herve
Mary, Jean-Yves
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (20) : 2173 - +
[38] FGFR3 Mutations Are an Adverse Prognostic Factor in Patients with t(4;14)(p16; q32) Multiple Myeloma: An Mmrf Commpass Analysis
Benard, Brooks
Christofferson, Austin
Legendre, Christophe
Aldrich, Jessica
Nasser, Sara
Yesil, Jennifer
Auclair, Daniel
Liang, Winnie
Lonial, Sagar
Keats, Jonathan J.
BLOOD, 2017, 130
[39] Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial
Nemec, Pavel
Zemanova, Zuzana
Kuglik, Petr
Michalova, Kyra
Tajtlova, Jana
Kaisarova, Petra
Oltova, Alexandra
Filkova, Hana
Holzerova, Milena
Balcarkova, Jana
Jarosova, Marie
Rabasova, Jana
Hruba, Martina
Spicka, Ivan
Gregora, Evzen
Adam, Zdenek
Scudla, Vlastimil
Maisnar, Vladimir
Schutzova, Miroslava
Hajek, Roman
LEUKEMIA & LYMPHOMA, 2012, 53 (05) : 920 - 927
[40] Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation
Neben, Kai
Jauch, Anna
Bertsch, Uta
Heiss, Christiane
Hielscher, Thomas
Seckinger, Anja
Mors, Tina
Mueller, Nadine Zoe
Hillengass, Jens
Raab, Marc S.
Ho, Anthony D.
Hose, Dirk
Goldschmidt, Hartmut
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (07): : 1150 - 1157

← 1 2 3 4 5 →